How Cosentyx Works to Reduce Inflammation
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein driving inflammation in autoimmune diseases. By binding to IL-17A, it blocks its activity, reducing inflammatory responses throughout the body.[1][2]
Conditions Where It Reduces Inflammation
Cosentyx treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. Clinical trials show it lowers inflammation markers like C-reactive protein (CRP) and improves symptoms by suppressing IL-17A-mediated pathways in skin, joints, and entheses.[1][3]
Evidence from Clinical Studies
In phase 3 trials for ankylosing spondylitis, 61% of patients on Cosentyx achieved ASAS20 response (20% symptom improvement) at week 16 versus 28% on placebo, with MRI evidence of reduced spinal inflammation.[3] Psoriasis studies reported 80-90% skin clearance, linked to decreased epidermal inflammation.[1] These effects stem from systemic IL-17A inhibition, confirmed in blood and tissue analyses.[2]
Does It Reduce Inflammation Everywhere in the Body?
Cosentyx primarily curbs IL-17A-driven inflammation but not all types (e.g., limited effect on TNF-alpha pathways). It circulates systemically via subcutaneous injection, reaching inflamed sites, but efficacy varies by disease—stronger in IL-17 dominant conditions.[2][4]
Common Side Effects Tied to Its Anti-Inflammatory Action
Patients report upper respiratory infections (11%), diarrhea (4%), and oral herpes (3%), often due to dampened immune inflammation. Serious risks include inflammatory bowel disease flare-ups in rare cases, highlighting pathway-specific effects.[1][5]
How Long Until Inflammation Drops?
Visible reductions start in 2-4 weeks for skin psoriasis; joint improvements take 4-16 weeks. Full effects build over months with weekly then monthly dosing.[3]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Approval Summary for Secukinumab
[3]: NEJM Trial on Secukinumab in Ankylosing Spondylitis
[4]: IL-17 Pathway Review (Nature Reviews)
[5]: Cosentyx Safety Data (FDA Post-Marketing)